Revolution Medicines, Inc.

Warp Drive Bio, Inc.

Ginkgo Bioworks, Inc.

Mathew Edward Sowa

Gregory Lawrence Verdine

Brian Roger Bowman

David M Armistead

Brian Yichiun Chow

David W White

Deborah Palestrant

Dylan Talbot Stiles

Sharon Ann Townson

Chris K Varma

Jay Paul Morgenstern

Uddhav Kumar Shigdel

Keith Earl Robison

Joshua Alan Van Dyke Blodgett

Neville J Anthony

Daniel C Gray

Matthew James Nichols

The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of the target protein. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of target protein activity.

Compounds that participate in cooperative binding and uses thereof

Disclosed herein are methods for identifying novel drug candidates.

Identifying new therapeutic agents

The present disclosure provides proteins, nucleic acids, vectors, and host molecules useful for the production of compounds of interest, and methods for their use.

Compositions and methods for the production of compounds

The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for ex ample through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of the target protein. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of target protein activity.

The invention relates to macrocyclic compounds capable of modulating biological processes through binding to a presenter protein and a target protein. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity. In some embodiment, the compounds of the invention 're-program' the binding of the presenter proteins to protein targets that either do not normally bind to the presenter protein.

Growing community of inventors

Watertown, MA, United States of America

Mathew Edward Sowa